- Home
- ESPR
as 11-08-2024 10:33am EST
Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment. Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The Company manages its business in one operating segment, which is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.
| Founded: | 2008 | Country: | United States |
| Employees: | N/A | City: | ANN ARBOR |
| Market Cap: | 319.2M | IPO Year: | 2013 |
| Target Price: | $8.17 | AVG Volume (30 days): | 3.4M |
| Analyst Decision: | Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.53 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.87 - $3.40 | Next Earning Date: | 11-07-2024 |
| Revenue: | $295,451,000 | Revenue Growth: | 187.12% |
| Revenue Growth (this year): | 199.6% | Revenue Growth (next year): | 19.36% |
Stock Insider Trading Activity of Esperion Therapeutics Inc. (ESPR)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Warren Eric | ESPR | Chief Commercial Officer | Oct 17 '24 | Sell | $2.12 | 107 | $226.73 | 162,552 | |
| Warren Eric | ESPR | Chief Commercial Officer | Sep 17 '24 | Sell | $1.78 | 2,608 | $4,650.06 | 162,552 | |
| Koenig Sheldon L. | ESPR | President and CEO | Sep 17 '24 | Sell | $1.80 | 14,550 | $26,131.80 | 752,266 | |
| Warren Eric | ESPR | Chief Commercial Officer | Aug 19 '24 | Sell | $1.95 | 211 | $410.61 | 162,552 |
Latest Esperion Therapeutics Inc. News
ESPR Breaking Stock News: Dive into ESPR Ticker-Specific Updates for Smart Investing
GuruFocus.com
9 hours ago
Esperion Therapeutics Inc (ESPR) Q3 2024 Earnings Call Highlights: Strong Revenue Growth Amidst ...
Zacks
a day ago
Esperion's Q3 Loss Wider Than Expected, Revenues Rise Y/Y
Zacks
a day ago
Esperion Therapeutics (ESPR) Reports Q3 Loss, Lags Revenue Estimates
Associated Press Finance
a day ago
Esperion Therapeutics: Q3 Earnings Snapshot
GlobeNewswire
a day ago
Esperion Reports Third Quarter 2024 Financial Results and Provides a Business Update
GlobeNewswire
4 days ago
Esperion to Participate in Upcoming Jefferies London Healthcare Conference
Zacks
8 days ago
Esperion Therapeutics (ESPR) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
GlobeNewswire
8 days ago
Esperion Announces a Featured Presentation in the Late Breaker/Featured Science Track and Three Poster Presentations Accepted for the 2024 American Heart Association (AHA) Scientific Sessions
Compare ESPR vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ESPR Esperion Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.